Indications: Yiqi Tongmai, promoting blood circulation and relieving pain. For qi deficiency and blood stasis type chest paralysis, symptoms include chest tightness, chest pain, shortness of breath, palpitations, spontaneous sweating, lack of complexion, fat tongue with tooth marks, dark or purple tongue or ecchymosis, pulse sinking; coronary heart disease Angina pectoris see the above symptoms.
Approval date: April 17, 2007
Modification date: July 23, 2019
Please read the instructions carefully and use under the guidance of a physician
Common name: Qishen Yiqi Dropping Pill
Phonetic script (Hanyu Pinyin): Qishenyiqi Diwan
[Ingredients] Astragalus membranaceus, Salvia miltiorrhiza, Panax notoginseng, and essential oil.
[Character] This product is a light brown to dark brown dripping pill; it is slightly fragrant and slightly bitter.
Or This product is a film-coated drip pill, which is light brown to dark brown after removing the coating; the gas is slightly fragrant and the taste is slightly bitter.
[Specifications] 0.5g per bag
0.52g per bag
[Usage and Dosage] Take half an hour after a meal. 1 bag at a time, 3 times a day. 4 weeks is a course of treatment or as directed by your doctor.
[Adverse reactions] Rare skin allergic reactions such as rash, itching, flushing; occasional nausea, vomiting, flatulence and other gastrointestinal discomfort.
[Contraindications] Those who have allergic reactions to this product are prohibited.
[Precautions] 1. Pregnant women and those with allergies should be used with caution; 2. If the patient has gastrointestinal reactions after taking the medicine, please consult a doctor.
[Clinical trial] This product was approved by the State Drug Administration in 2001 for 404 clinical trials.
[Pharmacology and Toxicology]
Preclinical pharmacodynamic tests have shown that this product can reduce the infarct size, improve ischemic electrocardiogram, reduce serum CK and LDH activity, lower plasma ET and TXB 2 levels, 6-keto-PGF 1a activity and The 6-keto-PGF 1a / TXB 2 ratio was increased; the infarct size of myocardial ischemia-reperfusion injury rats was reduced, and SOD activity was increased. This product can reduce the length of extracorporeal thrombus in rats, reduce the weight, and reduce the viscosity of plasma and whole blood. It can reduce the levels of TC, TG, LDL-C, VLDL-C in HDL-C Increased levels reduce the aortic TC content and liver TG and MDA content, and can reduce arachidonic acid and collagen-induced platelet aggregation rate; canine hemodynamic tests show that this product can be used to expand coronary blood vessels. Increased coronary flow reduces myocardial oxygen consumption index; without increasing left ventricular work, increases cardiac output and cardiac output.
[Packing] Polyester / aluminum / polyethylene compound film for pharmaceutical packaging, 15 bags per box; 9 bags per box.
[Validity Period] 24 months
[Executive standards] The first supplement of the 2015 edition of the Chinese Pharmacopoeia
[Approval number] National Medicine Standard Z20030139
National Medicine Standard Z20113048